Intranasal insulin treatment may have the potential to improve motor functions and verbal fluency in patients with Parkinson disease.
Intranasal insulin (INI) treatment may improve motor skills and verbal fluency in patients with Parkinson disease (PD), according to a new study in PLOS ONE.
The investigators conducted the study to determine the effects of INI on cognition and motor functions in patients with PD. INI treatment was administered with ViaNase, an electronic device that atomized insulin into an inhalable spray that could deliver the drug to the upper nasal cavity olfactory region and easily penetrate the brain.
Researchers stated that further studies are required to determine whether INI treatment can benefit patients with PD before they develop clinically significant cognitive impairment.
“Our study provided preliminary data that suggested an improvement of functional skills after four weeks of daily INI treatment that paves the way toward a larger cohort study to evaluate long-term safety and potential efficacy of intranasal insulin administration for potential treatment and prevention of functional decline in patients with Parkinson disease,” researchers concluded.